Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia

Overview

Journal Front Pharmacol

Date 2021 Oct 4

PMID 34603051

Citations 7

Authors

Jiahong Liu

Meihong Xiu

Haixia Liu

Jun Wang

Xirong Li

Affiliations

Soon will be listed here.

Abstract

Accumulating studies have shown that the pathophysiology of schizophrenia may be associated with aberrant lysophospolipid metabolism in the early stage of brain development. Recent evidence demonstrates that antipsychotic medication can regulate the phospholipase activity. However, it remains unclear whether lysophospolipid is associated with the therapeutic response to antipsychotic medication in schizophrenia. This study aimed to investigate the influence of olanzapine monotherapy on lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) and the association between symptom improvement and changes of LPC and LPE levels during treatment in antipsychotic-naïve first-episode (ANFE) patients. The psychotic symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS). 25 ANFE patients were treated with olanzapine for 1 mo. The levels of LPC and LPE were determined and psychotic symptoms were assessed at baseline and at 1-mo follow-up. Relative to baseline, the psychotic symptoms were significantly reduced after olanzapine treatment, except for negative symptoms. Moreover, the levels of most LPC and LPE increased after treatment. Interestingly, increased LPC(18:3) and LPC(20:2) levels were positively associated with the reduction rates of PANSS positive subscore. In addition, baseline levels of LPE(20:5), LPE(18:3) and LPE(22:5) were predictors for the reduction of positive symptoms. Our study reveals that the levels of lysophospolipid are associated with the improvement of positive symptoms, indicating that LPC may be a potential therapeutic target for olanzapine in schizophrenia. Moreover, baseline LPE levels were predictive biomarkers for the therapeutic response to olanzapine in the early stage of treatment in ANFE patients.

Citing Articles

Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.

Villate A, Olivares M, Usobiaga A, Unzueta-Larrinaga P, Barrena-Barbadillo R, Callado L Sci Rep. 2024; 14(1):31492.

PMID: 39733019 PMC: 11682106. DOI: 10.1038/s41598-024-83288-5.

Peripheral Lipid Signatures, Metabolic Dysfunction, and Pathophysiology in Schizophrenia Spectrum Disorders.

Wu S, Panganiban K, Lee J, Li D, Smith E, Maksyutynska K Metabolites. 2024; 14(9).

PMID: 39330482 PMC: 11434505. DOI: 10.3390/metabo14090475.

Metabolite profiling of peripheral blood plasma in pigs in early postnatal life fed whole bovine, caprine or ovine milk.

Jena A, Montoya C, Fraser K, Giezenaar C, Young W, Mullaney J Front Nutr. 2023; 10:1242301.

PMID: 37823089 PMC: 10564076. DOI: 10.3389/fnut.2023.1242301.

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study.

Zhao L, Liu H, Wang W, Wang Y, Xiu M, Li S Front Pharmacol. 2023; 14:1255501.

PMID: 37663259 PMC: 10470116. DOI: 10.3389/fphar.2023.1255501.

Targeted Lipidomics and Inflammation Response to Six Weeks of Sprint Interval Training in Male Adolescents.

Wang A, Zhang H, Liu J, Yan Z, Sun Y, Su W Int J Environ Res Public Health. 2023; 20(4).

PMID: 36834025 PMC: 9963480. DOI: 10.3390/ijerph20043329.

References

Cao B, Jin M, Brietzke E, McIntyre R, Wang D, Rosenblat J . Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design. Psychiatry Clin Neurosci. 2018; 73(3):100-108. DOI: 10.1111/pcn.12779. View

Kim M, Jung S, Kim S, Lee S, Lee J . Prehypertension-associated elevation in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidative stress. PLoS One. 2014; 9(5):e96735. PMC: 4011750. DOI: 10.1371/journal.pone.0096735. View

Lindon J, Holmes E, Nicholson J . So what's the deal with metabonomics?. Anal Chem. 2003; 75(17):384A-391A. DOI: 10.1021/ac031386+. View

Zhang C, Fang X, Yao P, Mao Y, Cai J, Zhang Y . Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha. Psychoneuroendocrinology. 2017; 81:138-143. DOI: 10.1016/j.psyneuen.2017.04.014. View

Leppik L, Parksepp M, Janno S, Koido K, Haring L, Vasar E . Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci. 2019; 270(1):59-70. DOI: 10.1007/s00406-018-0971-6. View

Gattaz W, Schmitt A, Maras A . Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res. 1995; 16(1):1-6. DOI: 10.1016/0920-9964(94)00060-l. View

Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G . Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry. 2004; 56(1):41-5. DOI: 10.1016/j.biopsych.2004.03.019. View

Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, Yao J, Nimgaonkar V . Impaired plasmalogens in patients with schizophrenia. Psychiatry Res. 2012; 198(3):347-52. DOI: 10.1016/j.psychres.2012.02.019. View

Shen H, Wu D, Wang S, Zhao M, Sun W, Zhu X . Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. Basic Clin Pharmacol Toxicol. 2018; 123(6):756-765. DOI: 10.1111/bcpt.13079. View

10.

Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G . Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol Psychiatry. 2005; 57(4):399-405. DOI: 10.1016/j.biopsych.2004.11.018. View

11.

Frasch S, Zemski-Berry K, Murphy R, Borregaard N, Henson P, Bratton D . Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol. 2007; 178(10):6540-8. DOI: 10.4049/jimmunol.178.10.6540. View

12.

Tsukahara T, Hara H, Haniu H, Matsuda Y . The Combined Effects of Lysophospholipids against Lipopolysaccharide-induced Inflammation and Oxidative Stress in Microglial Cells. J Oleo Sci. 2021; 70(7):947-954. DOI: 10.5650/jos.ess21069. View

13.

Kaddurah-Daouk R, Kristal B, Weinshilboum R . Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008; 48:653-83. DOI: 10.1146/annurev.pharmtox.48.113006.094715. View

14.

Kaddurah-Daouk R, McEvoy J, Baillie R, Lee D, Yao J, Doraiswamy P . Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007; 12(10):934-45. DOI: 10.1038/sj.mp.4002000. View

15.

Xiu M, Li Z, Chen D, Chen S, Curbo M, Wu H . Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia. Schizophr Bull. 2020; 46(6):1498-1510. PMC: 7707068. DOI: 10.1093/schbul/sbaa062. View

16.

Liu J, Chen N, Guo Y, Guan X, Wang J, Wang D . Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. J Psychiatr Res. 2021; 140:409-415. DOI: 10.1016/j.jpsychires.2021.06.001. View

17.

Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T . Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry. 1999; 156(8):1205-8. DOI: 10.1176/ajp.156.8.1205. View

18.

Matsuda Y, Haniu H, Tsukahara T, Uemura T, Inoue T, Sako K . Oral administration of porcine liver decomposition product for 4 weeks enhances visual memory and delayed recall in healthy adults over 40 years of age: A randomized, double-blind, placebo-controlled study. Exp Gerontol. 2020; 141:111064. DOI: 10.1016/j.exger.2020.111064. View

19.

Hishikawa D, Hashidate T, Shimizu T, Shindou H . Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. J Lipid Res. 2014; 55(5):799-807. PMC: 3995458. DOI: 10.1194/jlr.R046094. View

20.

Zhang Y, Fang X, Fan W, Tang W, Cai J, Song L . Interaction between BDNF and TNF-α genes in schizophrenia. Psychoneuroendocrinology. 2018; 89:1-6. DOI: 10.1016/j.psyneuen.2017.12.024. View